Robert Celt
New Member
Cannabis Science, which is developing cannabis based medicines, said it has started the New Year healthier than ever before.
Cannabis Science (OTC PINK: CBIS), which is developing cannabis based medicines, said it has started the New Year healthier than ever before.
"2015 was a great year of growth for our company," said president and co-founder Raymond C. Dabney.
"We made a great deal of progress with our drug development, acquisition strategy, product roll out, and strategic partnership search."
"We are kicking off the new year with new products already brought to market -- a huge head start over last year. We look forward to announcing all of our ground-breaking progress, step by step, along the way."
The company is focused on development of three main drug targets - CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1 with an initial focus on skin cancers, HIV/AIDS, and neurological conditions.
It wants to accelerate these programmes and gain regulatory approval as the industry is expected to reach US$1.2 trillion globally by 2018.
In California, it is seeing success with initial production and testing of its Pure Decarboxylated CO2 Oil (PDCO) and CBD, Sativa, and Indica Capsule products during the last quarter of 2015.
News Moderator: Robert Celt 420 MAGAZINE ®
Full Article: Cannabis Science Embarking On 2016 In Good Health
Author: Giles Gwinnett
Contact: ProActive Investors
Photo Credit: Cannabis in Canada
Website: ProActive Investors
Cannabis Science (OTC PINK: CBIS), which is developing cannabis based medicines, said it has started the New Year healthier than ever before.
"2015 was a great year of growth for our company," said president and co-founder Raymond C. Dabney.
"We made a great deal of progress with our drug development, acquisition strategy, product roll out, and strategic partnership search."
"We are kicking off the new year with new products already brought to market -- a huge head start over last year. We look forward to announcing all of our ground-breaking progress, step by step, along the way."
The company is focused on development of three main drug targets - CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1 with an initial focus on skin cancers, HIV/AIDS, and neurological conditions.
It wants to accelerate these programmes and gain regulatory approval as the industry is expected to reach US$1.2 trillion globally by 2018.
In California, it is seeing success with initial production and testing of its Pure Decarboxylated CO2 Oil (PDCO) and CBD, Sativa, and Indica Capsule products during the last quarter of 2015.
News Moderator: Robert Celt 420 MAGAZINE ®
Full Article: Cannabis Science Embarking On 2016 In Good Health
Author: Giles Gwinnett
Contact: ProActive Investors
Photo Credit: Cannabis in Canada
Website: ProActive Investors
